Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May;182(5):2453-2454.
doi: 10.1007/s00431-023-04877-6. Epub 2023 Feb 27.

Letter to the Editor, regarding Li L, Zhu X, Chen X, Gao J, Ding C, et al. Advances in targeted therapy for pulmonary arterial hypertension in children. Eur J Pediatr. 2022 Dec 17

Maurice Beghetti  1 , Dunbar Ivy  2 , Nicola Scott  3 , Sandra Machlitt-Northen  3 , Mary Ann Lukas  4
Affiliations
Comment

Letter to the Editor, regarding Li L, Zhu X, Chen X, Gao J, Ding C, et al. Advances in targeted therapy for pulmonary arterial hypertension in children. Eur J Pediatr. 2022 Dec 17

Maurice Beghetti et al. Eur J Pediatr. 2023 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

For Dunbar Ivy, the University of Colorado contracts with GSK, Actelion, Eli Lilly, and United Therapeutics to be a consultant. Maurice Beghetti reports remunerations for lectures and/or consultancy from Actelion, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline (GSK), Merck Sharp & Dohme, and Pfizer and unrestricted research grants from Actelion and Bayer. Mary Ann Lukas, Nicola Scott, and Sandra Machlitt-Northen are employees of GSK and hold shareholder status in the company.

Comment on

References

    1. Li L, Zhu X, Chen X, Gao J, Ding C et al (2022) Advances in targeted therapy for pulmonary arterial hypertension in children. Eur J Pediatr - PubMed
    1. Volibris Product Information https://www.ema.europa.eu/en/documents/product-information/volibris-epar.... Accessed 12 Jan 2023
    1. Ivy D, Beghetti M, Juaneda-Simian E, et al. A randomized study of safety and efficacy of two doses of ambrisentan to treat pulmonary arterial hypertension in pediatric patients aged 8 years up to 18 years. J Pediatr X. 2020;5:100055. - PMC - PubMed
    1. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, ESC/ERS Scientific Document Group et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. doi: 10.1183/13993003.00879-2022. - DOI - PubMed
    1. Laffan S, Kohrs L, Kambara T, Rambo M, Jucker B et al (2019) Brain weight effect of ambrisentan in juvenile rats associated with breathing sounds, apnea and sustained hypoxemia. Presented at the 59th Teratology Society Annual Meeting, San Diego, CA